共 50 条
miR-10b-5p is a novel Th17 regulator present in Th17 cells from ankylosing spondylitis
被引:59
|作者:
Chen, L.
[2
]
Al-Mossawi, M. H.
[2
]
Ridley, A.
[2
]
Sekine, T.
[2
]
Hammitzsch, A.
[2
,3
]
de Wit, J.
[2
]
Simone, D.
[2
]
Shi, H.
[2
]
Penkava, F.
[2
]
Kurowska-Stolarska, M.
[4
]
Pulyakhina, I.
[5
]
Knight, J. C.
[6
]
Kim, T. J.
[1
]
Bowness, P.
[2
,7
]
机构:
[1] Chonnam Natl Univ, Med Sch & Hosp, Dept Rheumatol, 42 Jebong Ro, Gwangju, South Korea
[2] Univ Oxford, Nuffield Dept Orthopaed Rheumatol & Musculoskelet, Oxford, England
[3] Tech Univ Munich, Dept Nephrol, Klinikum Rechts Isar, Munich, Germany
[4] Univ Glasgow, Inst Infect Immun & Inflammat, Glasgow, Lanark, Scotland
[5] Wellcome Trust Ctr Human Genet, Oxford, England
[6] Univ Oxford, Nuffield Dept Med, Wellcome Trust Ctr Human Genet, Oxford, England
[7] Natl Inst Hlth Res, Oxford Musculoskeletal Biomed Res Unit, Oxford, England
基金:
英国惠康基金;
关键词:
AUTOIMMUNE INFLAMMATION;
MICRORNA;
DIFFERENTIATION;
CANCER;
D O I:
10.1136/annrheumdis-2016-210175
中图分类号:
R5 [内科学];
学科分类号:
1002 ;
100201 ;
摘要:
Objective To determine the microRNA (miR) signature in ankylosing spondylitis (AS) T helper (Th) 17 cells. Methods Interleukin (IL)-17A-producing CD4+ T cells from patients with AS and healthy controls were FACS-sorted for miR sequencing and qPCR validation. miR-10b function was determined by miR mimic expression followed by cytokine measurement, transcriptome analysis, qPCR and luciferase assays. Results AS Th17 cells exhibited a miR signature characterised by upregulation of miR-155-5p, miR-210-3p and miR-10b. miR-10b has not been described previously in Th17 cells and was selected for further characterisation. miR-10b is transiently induced in in vitro differentiated Th17 cells. Transcriptome, qPCR and luciferase assays suggest that MAP3K7 is targeted by miR-10b. Both miR-10b overexpression and MAP3K7 silencing inhibited production of IL-17A by both total CD4 and differentiating Th17 cells. Conclusions AS Th17 cells have a specific miR signature and upregulate miR-10b in vitro. Our data suggest that miR-10b is upregulated by proinflammatory cytokines and may act as a feedback loop to suppress IL-17A by targeting MAP3K7. miR-10b is a potential therapeutic candidate to suppress pathogenic Th17 cell function in patients with AS.
引用
收藏
页码:620 / 624
页数:5
相关论文